CN101702921A - 个体化治疗的处理方法 - Google Patents

个体化治疗的处理方法 Download PDF

Info

Publication number
CN101702921A
CN101702921A CN200780050039A CN200780050039A CN101702921A CN 101702921 A CN101702921 A CN 101702921A CN 200780050039 A CN200780050039 A CN 200780050039A CN 200780050039 A CN200780050039 A CN 200780050039A CN 101702921 A CN101702921 A CN 101702921A
Authority
CN
China
Prior art keywords
ams
drug
folate
plasma
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780050039A
Other languages
English (en)
Chinese (zh)
Inventor
艾力·阿尔佐曼
格林·卡瓦萨琪
迈克尔·钱斯勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accium Biosciences
Original Assignee
Accium Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accium Biosciences filed Critical Accium Biosciences
Publication of CN101702921A publication Critical patent/CN101702921A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200780050039A 2006-11-17 2007-11-17 个体化治疗的处理方法 Pending CN101702921A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85973906P 2006-11-17 2006-11-17
US60/859,739 2006-11-17
PCT/US2007/085033 WO2008064138A2 (en) 2006-11-17 2007-11-17 Personalized therapeutic treatment process

Publications (1)

Publication Number Publication Date
CN101702921A true CN101702921A (zh) 2010-05-05

Family

ID=39430529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780050039A Pending CN101702921A (zh) 2006-11-17 2007-11-17 个体化治疗的处理方法

Country Status (7)

Country Link
EP (1) EP2094861A4 (enExample)
JP (1) JP2010510495A (enExample)
CN (1) CN101702921A (enExample)
AU (1) AU2007323782A1 (enExample)
BR (1) BRPI0719314A2 (enExample)
CA (1) CA2669864A1 (enExample)
WO (1) WO2008064138A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017101171A1 (zh) * 2015-12-19 2017-06-22 开滦总医院 溶栓药物个体化应用剂量的体外测定试验方法
EP4046161A4 (en) * 2019-10-18 2023-11-29 National University of Singapore METHOD FOR PREDICTING APPROPRIATE THERAPY

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0714040D0 (en) * 2007-07-19 2007-08-29 Xceleron Ltd Quantification of analytes
US20200116657A1 (en) * 2018-10-15 2020-04-16 Olaris, Inc. Nmr-metabolite-signature for identifying cancer patients resistant to cdk4/6 inhibitors, endocrine therapy and anti-her2 therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131544A (en) * 1976-08-03 1978-12-26 Nasik Elahi Macroencapsulated sorbent element and process for using the same
US4880014A (en) * 1987-08-14 1989-11-14 Zarowitz Barbara J Method for determining therapeutic drug dosage using bioelectrical resistance and reactance measurements
GB0304433D0 (en) * 2003-02-27 2003-04-02 Xceleron Ltd Improvements relating to chemical libraries
WO2004090537A2 (en) * 2003-04-02 2004-10-21 Celator Pharmaceuticals, Inc. Methods to individualize combination therapy
US7662097B2 (en) * 2004-09-20 2010-02-16 Resonant Medical, Inc. Radiotherapy treatment monitoring using ultrasound
EP1810315B1 (en) * 2004-10-28 2014-12-03 Albert Edward Litherland Method and apparatus for separation of isobaric interferences
GB0504243D0 (en) * 2005-03-02 2005-04-06 Xceleron Ltd Biological compositions labelled with radioisotope

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017101171A1 (zh) * 2015-12-19 2017-06-22 开滦总医院 溶栓药物个体化应用剂量的体外测定试验方法
EP4046161A4 (en) * 2019-10-18 2023-11-29 National University of Singapore METHOD FOR PREDICTING APPROPRIATE THERAPY

Also Published As

Publication number Publication date
AU2007323782A1 (en) 2008-05-29
BRPI0719314A2 (pt) 2014-02-04
JP2010510495A (ja) 2010-04-02
EP2094861A2 (en) 2009-09-02
WO2008064138A3 (en) 2009-01-15
WO2008064138A2 (en) 2008-05-29
CA2669864A1 (en) 2008-05-29
EP2094861A4 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
Wang et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT-independent pathway
Natarajan et al. Development of novel immunoPET tracers to image human PD-1 checkpoint expression on tumor-infiltrating lymphocytes in a humanized mouse model
Graf et al. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy
Sparreboom et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)
Madar et al. Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium
Dubbelman et al. Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas
Liao et al. Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly (ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
James et al. Absorption, distribution, metabolism, and excretion of [14C] BYL719 (alpelisib) in healthy male volunteers
Van Andel et al. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients
Li et al. Utility of 211At-trastuzumab for the treatment of metastatic gastric cancer in the liver: evaluation of a preclinical α-radioimmunotherapy approach in a clinically relevant mouse model
Zhang et al. A mass balance study of [14C] SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
CN101702921A (zh) 个体化治疗的处理方法
Kraihammer et al. Improved quality control of [177Lu] Lu-PSMA I&T
Bigott et al. Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi
Ahmed et al. Metabolic alterations in sputum and exhaled breath condensate of early stage non-small cell lung cancer patients after surgical resection: a pilot study
Zhou et al. Mitochondrial uptake of aristolactam I plays a critical role in its toxicity
Qin et al. Signaling Network Response to α-Particle–Targeted Therapy with the 225Ac-Labeled Minigastrin Analog 225Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors
Dai et al. Mass balance and pharmacokinetics of an oral dose of 14C‐napabucasin in healthy adult male subjects
Liu et al. Metabolic profiles of neratinib in rat by using ultra‐high‐performance liquid chromatography coupled with diode array detector and Q‐Exactive Orbitrap tandem mass spectrometry
Dueker et al. Quantifying exploratory low dose compounds in humans with AMS
Roffel et al. The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future
MacDonald et al. Phase I study of orally administered 14Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies
Ghosh et al. Preparation and evaluation of 177Lu-Labeled gemcitabine: an effort toward developing radiolabeled chemotherapeutics for targeted therapy applications
AU2014202609A1 (en) Personalized therapeutic treatment process
Medhora et al. Radiation increases bioavailability of lisinopril, a mitigator of radiation-induced toxicities

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100505